RIVAC-INC.
7.8.2019 11:02:06 CEST | Business Wire | Press release
RIVAC Inc. has announced the release of an iPhone App 'FrontShot' that enables real-time display and shooting of a straight frontal view of any plane, even if the camera is pointed from an oblique direction. Operation is simple, and you can see a straight frontal view of any plane, such as a document or wall, through the camera.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190807005001/en/
Official website: https://www.english.rivac.co.jp
[Background of FrontShot development]
There are times when you want to shoot a straight frontal view of an object such as a document, wall, poster, or time-table. In cases like this, it is convenient if you can just point your camera from an oblique direction, and see the straight frontal view. FrontShot was developed to make this possible. Even if you point your camera from an oblique direction, any sort of plane —documents, walls, etc.— can be viewed as a straight frontal image.
[Features]
Has three modes: horizontal plane, vertical plane, and slanted plane.
- Can handle any plane
The app can handle not only horizontal and vertical planes, but also slanted planes, and thus it is possible to see a straight frontal view of any plane. Naturally, it is also possible to see straight frontal views of ceilings. (Ceilings are regarded as horizontal planes.)
- Simple operation
Operation is extremely simple. For a horizontal plane, no special operation is necessary. Simply point the camera, and the straight frontal image will appear. For a vertical or slanted plane, the orientation of the plane must be designated (automatically or manually), but if the mode is set to automatic, a straight frontal image will appear just by pointing the camera, as with a horizontal plane. Operation is simple in manual mode too. Just point the camera in the direction of the plane, and press the button. A straight frontal image of the plane will appear.
*In the automated mode for vertical and slanted planes, the system calculates the direction of the plane by recognizing the horizontal and vertical lines which appear.
- Display in real-time
Processing is performed at high speed using our unique technology, and this makes it possible to display straight frontal images in real-time.
[Uses]
The app can be used for a variety purposes including: documents, posters, whiteboards, time-tables, buildings, signs, pictures, lettering and pictures drawn on the ground, and online sale items (clothes, books, CDs, other flat items).
[App information]
App name |
: |
FrontShot |
Device |
: |
iPhone (iOS9 or later) |
Category |
: |
Photo & Video |
Price |
: |
Check at the App Store. (A free trial is available. The product version can be purchased from the free version via in-app purchase.) |
| Released | : | August 5, 2019 |
iTunes URL |
: |
|
Official website |
: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom